•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
PowerGEM Secures Strategic Growth Investment from General Atlantic and Announces Acquisition of Telos Energy
Telos Q1 Earnings Call Highlights
Telos Corporation (TLS) Q1 2026 Earnings Call Transcript
Telos Corporation (TLS) Q1 Earnings and Revenues Top Estimates
Telos Corporation Announces First Quarter 2026 Earnings
Telos Corporation to Participate in Upcoming Investor Conferences
Telos Corporation (TLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Young Travelers Can Save $20 on TSA PreCheck Enrollment Starting May 1
Why Telos (TLS) Could Beat Earnings Estimates Again
Telos Corporation to Announce First Quarter 2026 Financial Results on May 11, 2026
Telos Corporation to Announce First Quarter 2026 Financial Results on May 11, 2026
Telos Expands TSA PreCheck Enrollment with New Location at Elko Regional Airport
Telos, University of Central Florida Launch TSA PreCheck Enrollment on Campus
Telos: New FedRAMP Certification And Strong Growth Plan For 2026
Telos Corporation's Xacta Platform Achieves Full FedRAMP High Authorization with Addition of Xacta.io and Xacta.ai
Telos (NASDAQ:TLS) and DXC Technology (NYSE:DXC) Head-To-Head Analysis
Head to Head Analysis: Grid Dynamics (NASDAQ:GDYN) & Telos (NASDAQ:TLS)
Telos (NASDAQ:TLS) EVP Sells $259,398.54 in Stock